BWI: Ipca Laboratories Q1 FY10 Results

Press release from Business Wire India
Source: Ipca Laboratories Limited
Thursday, July 30, 2009 03:07 PM IST (09:37 AM GMT)
Editors: General: Consumer interest, Economy; Business: Banking & financial services, Business services, Financial Analyst, Healthcare, biotechnology & pharmaceutical, Stock exchanges; Healthcare
--------------------------------------------------
Ipca Laboratories Q1 FY10 Results
Net Total Income at Rs. 363.05 crores Up by 23%, EBITDA at Rs. 71.86 crores Up by 21%, Net Profit at Rs. 49.77 crores Up by 111%

Mumbai, Maharashtra, India, Thursday, July 30, 2009 -- (Business Wire India) -- Ipca Laboratories Limited today announced its unaudited financial results for the first quarter ended 30th June, 2009 of the financial year 2009-10.

Key Highlights of Q1 FY10

-- Net Total Income at Rs. 363.05 crores in Q1 FY10 as against Rs. 295.30 crores in Q1 FY09, growth of 23%.

-- Export Income at Rs. 175.20 crores in Q1 FY10 as against Rs. 152.52 crores in Q1 FY09, growth of 15%.

-- Revenue from Indian branded formulations business at Rs. 144.90 crores in Q1 FY10 as against Rs. 116.39 crores in Q1 FY09, growth of 24%.

-- Export Revenue from formulations at Rs. 94.63 crores in Q1 FY10 as against Rs. 89.00 crores in Q1 FY09, growth of 6%.

-- Revenue from formulations business at Rs. 239.53 crores in Q1 FY10 as against Rs. 205.39 crores in Q1 FY09, growth of 17%.

-- Revenues from Indian Active Pharmaceutical Ingredients (APIs) business at Rs.37.67 crores in Q1 FY10 as against Rs. 23.85 crores in Q1 FY09, growth of 58%.

-- Export Revenue from Active Pharmaceutical Ingredients (APIs) at Rs.80.57crores in Q1 FY10 as against Rs. 63.52 crores in Q1 FY09, growth of 27%.

-- Revenues from Active Pharmaceutical Ingredients (APIs) business at Rs. 118.24 crores in Q1 FY10 as against Rs. 87.37 crores in Q1 FY09, growth of 35%.

-- EBITDA at Rs. 71.86 crores in Q1 FY10 as against Rs. 59.54 crores in Q1 FY09, growth of 21%.

-- EBITDA margin @ 20%.

-- Net Profit at Rs. 49.77 crores in Q1 FY10 as against Rs. 23.63 crores in Q1 FY09, growth of 111%.

-- EPS of Rs. 19.86 in Q1 FY10 as against Rs. 9.38 in Q1 FY09.

-- Till date, the Company has filed 13 ANDAs with US-FDA out of which 9 ANDAs are granted.

-- 46 DMFs are also filed with US-FDA for Active Pharmaceutical Ingredients (APIs).

About Ipca Laboratories:

Ipca Laboratories is a fast growing pharmaceutical major, with a strong thrust on exports. Exports to over 110 countries, now account for nearly half of Company's income. Ipca Laboratories is vertically integrated and produces finished dosage forms and Active Pharmaceutical Ingredients.

To view the Press Release along with the tables and the Unaudited Financial Results, click the links below:

Press Release

Unaudited Financial Results
For picture(s)/data to illustrate this release click below:

http://www.BusinessWireIndia.com/attachments/Press_Release(32).doc
Press_Release(32).doc
http://www.BusinessWireIndia.com/attachments/Q1.doc
Q1.doc


CONTACT DETAILS
A. K. Jain, Executive Director, Ipca Laboratories Limited, +91 (22) 66474654, ajit@ipca.co.in
Harish P. Kamath, V.P. Legal & Company Secretary, Ipca Laboratories Limited, +91 (22) 66474644, harish@ipca.co.in

KEYWORDS
CONSUMER, ECONOMY, BANKING, BUSINESS SERVICES, Financial Analyst, HEALTHCARE, STOCK EXCHANGES, HEALTHCARE, IPCALAB.BO, IPCALAB.NS

If you wish to change your Business Wire India selection please click on this link http://www.businesswireindia.com/media/news.asp and use your personal username and password to login.

Submit your press release at http://www.businesswireindia.com